EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

24 Jun 2025 08:00 CEST

Oslo, Norway, 24 June 2025. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce first patient
dosed in its ENACT trial.

The trial is a multi-centre, open-label Phase 2 clinical trial testing the
safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with
standard of care (modified FOLFIRINOX chemotherapy) in first line patients with
borderline resectable or unresectable locally advanced pancreatic cancer.

“We are excited to have the first pancreatic cancer patient treated with ACT at
our first U.S. site. More than 500,000 patients are diagnosed with pancreatic
cancer each year globally, and pancreatic cancer is one of the deadliest types
of cancer, with limited and often ineffective treatment options. This trial
addresses the significant unmet medical need and the urge to advance novel
treatment options for this patient population. We are on track with the opening
of sites for patient recruitment and initial safety data are expected in 2025.”
said Per Walday, Chief Executive Officer of EXACT Therapeutics.

Dosing of the first patient in the Phase 2 trial follows the announcement of
positive final efficacy and safety data in the Phase 1 trial in patients with
liver metastases of colorectal origin.

The Phase 2 trial will enroll up to 25 patients in the U.S., U.K. and Europe,
and has the ClinicalTrials.gov Identifier: NCT06850623.

About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics’
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here: www.exact-tx.com

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

Forward looking statements:
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.

More information:
Access the news on Oslo Bors NewsWeb site